This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Ion PGM™ Solution Outperforms Competitor On Major Performance Metrics For Benchtop Sequencing

CARLSBAD, Calif., May 14, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that Ion PGM™ now significantly outperforms its competitor on the major performance metrics for benchtop sequencing. It offers the simplest and fastest workflow, lowest cost-per-sample, and highest sensitivity for multiple basic and clinical research applications—all on a sequencer that is a fraction of the cost of the alternative.  

The performance gains are the result of upfront sample prep automation, new Ion PGM™ semiconductor chips that deliver up to 10-fold greater throughput, and improved variant-calling software. Life Technologies is also shipping a redesigned Ion PGM™ Sequencer priced 30 percent less than the original, a savings realized by leveraging the significant economies of scale in electronics manufacturing. See http://www.lifetechnologies.com/pgm for more.

"Ion PGM™ and Ion AmpliSeq™ technology have transformed gene panel sequencing by making it faster, simpler, and more accessible, and that's made us the number-one benchtop sequencer in the market," said Maneesh Jain, VP of Marketing at Ion Torrent. "Today's new advances make gene panel sequencing on the Ion platform superior to our competitor by every major performance metric."

Ion AmpliSeq™ gene panels enable scientists to amplify over 6,000 targets in a single tube in 3.5 hours with only 10 ng of input sample. In the past 18 months, over 1,500 scientists have designed more than 5,000 different Ion AmpliSeq™ gene panels, indicating broad adoption of this game-changing technology.  

Simplest and fastest* workflow: automated solution for gene panel sequencingTogether, Ion AmpliSeq™ gene panels and the Ion PGM™ System deliver the industry's simplest and fastest gene panel workflow. The upcoming Ion Chef™ System provides a fully automated solution for sample prep up front of the Ion PGM™ and Ion Proton™ sequencers. This enables a sample-to-result workflow that far outperforms our competitor, with a more than two-fold advantage in turnaround time, hands-on time, and number of pipetting steps. 

Best accuracy: up to 100 percent sensitivity for multiple gene panelsIn the past, researchers transitioning from studying individual genes and mutations, to sequencing gene panels were seriously challenged by identifying all the mutations present in the sample. Ion AmpliSeq™ technology coupled with the new, tunable Torrent Suite v3.6 software provides up to 100 percent sensitivity for multiple panels, enabling researchers to see their variants of interest. Additionally, the new Ion Reporter 1.6 Software enables researchers to rapidly annotate and filter variants, completing the gene panel design and analysis workflow.

Two research groups that used an Ion AmpliSeq™ Community panel for sequencing the BRCA1 and BRCA2 genes recently showed the accuracy and sensitivity of Ion PGM™ technology. The genes, which have been implicated in hereditary breast and ovarian cancers, are often difficult to sequence because there are many mutations scattered throughout the gene, including many truncating mutations and homopolymer regions. 

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs